Free Trial

Sanofi (SNY) Competitors

Sanofi logo
$52.90 +0.01 (+0.02%)
Closing price 04:00 PM Eastern
Extended Trading
$52.88 -0.02 (-0.03%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SNY vs. NVO, NVS, AZN, GSK, TAK, ARGX, BNTX, ONC, TEVA, and SMMT

Should you be buying Sanofi stock or one of its competitors? The main competitors of Sanofi include Novo Nordisk A/S (NVO), Novartis (NVS), AstraZeneca (AZN), GSK (GSK), Takeda Pharmaceutical (TAK), argenx (ARGX), BioNTech (BNTX), Beigene (ONC), Teva Pharmaceutical Industries (TEVA), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical products" industry.

Sanofi vs.

Sanofi (NASDAQ:SNY) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, community ranking, profitability, media sentiment, earnings, risk and valuation.

Novo Nordisk A/S received 382 more outperform votes than Sanofi when rated by MarketBeat users. Likewise, 61.74% of users gave Novo Nordisk A/S an outperform vote while only 61.18% of users gave Sanofi an outperform vote.

CompanyUnderperformOutperform
SanofiOutperform Votes
52
61.18%
Underperform Votes
33
38.82%
Novo Nordisk A/SOutperform Votes
434
61.74%
Underperform Votes
269
38.26%

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Novo Nordisk A/S has a net margin of 34.81% compared to Sanofi's net margin of 12.77%. Novo Nordisk A/S's return on equity of 84.68% beat Sanofi's return on equity.

Company Net Margins Return on Equity Return on Assets
Sanofi12.77% 25.61% 14.72%
Novo Nordisk A/S 34.81%84.68%26.29%

Novo Nordisk A/S has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sanofi$45.17B2.96$6.02B$2.8018.89
Novo Nordisk A/S$303.14B1.01$14.64B$3.3820.18

Sanofi pays an annual dividend of $1.60 per share and has a dividend yield of 3.0%. Novo Nordisk A/S pays an annual dividend of $1.63 per share and has a dividend yield of 2.4%. Sanofi pays out 57.1% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 48.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Sanofi has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500.

In the previous week, Novo Nordisk A/S had 27 more articles in the media than Sanofi. MarketBeat recorded 66 mentions for Novo Nordisk A/S and 39 mentions for Sanofi. Sanofi's average media sentiment score of 1.03 beat Novo Nordisk A/S's score of 0.55 indicating that Sanofi is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sanofi
24 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Novo Nordisk A/S
29 Very Positive mention(s)
9 Positive mention(s)
14 Neutral mention(s)
12 Negative mention(s)
1 Very Negative mention(s)
Positive

Sanofi presently has a consensus price target of $63.33, suggesting a potential upside of 19.72%. Novo Nordisk A/S has a consensus price target of $135.00, suggesting a potential upside of 97.97%. Given Novo Nordisk A/S's higher probable upside, analysts plainly believe Novo Nordisk A/S is more favorable than Sanofi.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sanofi
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
3 Strong Buy rating(s)
3.14
Novo Nordisk A/S
2 Sell rating(s)
5 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.38

Summary

Novo Nordisk A/S beats Sanofi on 13 of the 21 factors compared between the two stocks.

Get Sanofi News Delivered to You Automatically

Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SNY vs. The Competition

MetricSanofiPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$133.64B$6.52B$5.37B$8.39B
Dividend Yield3.16%2.65%5.22%4.10%
P/E Ratio21.248.9226.8419.71
Price / Sales2.96253.80392.34117.39
Price / Cash10.1665.8538.2534.62
Price / Book1.596.466.794.50
Net Income$6.02B$143.98M$3.23B$248.18M
7 Day Performance7.50%3.04%4.07%1.14%
1 Month Performance3.87%7.44%12.52%15.20%
1 Year Performance8.07%-2.46%16.83%6.56%

Sanofi Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SNY
Sanofi
4.0417 of 5 stars
$52.90
+0.0%
$63.33
+19.7%
+9.2%$133.64B$45.17B21.2491,600Positive News
NVO
Novo Nordisk A/S
4.6803 of 5 stars
$66.71
+3.6%
$135.00
+102.4%
-48.7%$299.36B$303.14B20.2854,400Trending News
NVS
Novartis
1.4912 of 5 stars
$110.47
+0.8%
$123.38
+11.7%
+9.2%$233.36B$53.22B18.79101,700Positive News
AZN
AstraZeneca
3.5212 of 5 stars
$69.53
+1.0%
$88.00
+26.6%
-9.3%$215.63B$54.98B30.7783,500Positive News
GSK
GSK
1.9371 of 5 stars
$37.87
+0.6%
$40.58
+7.2%
-13.9%$78.13B$31.53B23.8290,100Positive News
TAK
Takeda Pharmaceutical
3.3174 of 5 stars
$14.22
+0.8%
N/A+7.2%$45.25B$4.58T35.5547,300Positive News
ARGX
argenx
3.2924 of 5 stars
$575.49
+1.7%
$698.11
+21.3%
+59.9%$35.14B$2.58B-653.97650Positive News
Gap Up
BNTX
BioNTech
2.7976 of 5 stars
$97.41
+5.0%
$142.08
+45.9%
+10.0%$23.42B$2.75B-46.393,080Trending News
ONC
Beigene
2.6878 of 5 stars
$232.90
+2.0%
$319.00
+37.0%
N/A$23.07B$4.18B-28.269,000
TEVA
Teva Pharmaceutical Industries
3.2851 of 5 stars
$16.95
+0.1%
$24.43
+44.1%
-0.4%$19.22B$16.62B-11.6936,800Positive News
Options Volume
SMMT
Summit Therapeutics
3.1745 of 5 stars
$23.79
-0.3%
$37.40
+57.2%
+437.2%$17.67B$700,000.00-84.96110Positive News

Related Companies and Tools


This page (NASDAQ:SNY) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners